Dr. Gregory W. Albers Receives the Distinguished Clinical Research Achievement Award for Stroke Research

Dr. Albers, Co-Founder of iSchemaView, led the Ground-Breaking DEFUSE 3
Study That Contributed to New American Heart Association and American
Stroke Association Guidelines for Thrombectomy

WASHINGTON–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CRFTopTen?src=hash” target=”_blank”gt;#CRFTopTenlt;/agt;–iSchemaView, the worldwide leader in advanced imaging for stroke care
and research, is proud to announce that iSchemaView co-founder Dr.
Gregory Albers has received the highly respected Distinguished Clinical
Research Achievement Award, presented by the Clinical Research Forum.

The Distinguished Clinical Research Achievement Awards are presented to
the top two studies that show creativity, innovation, or a novel
approach that demonstrates an immediate impact on the health and
well-being of patients.

In the DEFUSE 3 study, Dr. Albers and his team used iSchemaView’s RAPID™
advanced medical imaging platform, exclusively, to identify stroke
patients who continue to have salvageable brain tissue many hours after
stroke onset. By identifying patients who are most likely to benefit
from stroke therapies, the DEFUSE 3 study is credited with accelerating
the development and testing of new therapeutic options, as well as
enabling hospitals to offer life-saving stroke therapies to many
patients who arrive after the previous standard six-hour treatment
window has elapsed.

Dr. Albers is the Coyote Foundation professor of neurology and
neurological sciences, and professor, by courtesy, of neurosurgery at
the Stanford University Medical Center. He is also director of
the Stanford Stroke Center. Dr. Albers’ primary research focus is the
diagnosis, management and prevention of ischemic stroke. He was
instrumental in the development of RAPID, a medical imaging platform
that allows physicians to identify stroke patients who have salvageable
brain tissue. Due to the findings of DEFUSE 3 and other groundbreaking
stroke studies that also employed RAPID, the American Heart Association
and American Stroke Association changed their treatment guidelines for
thrombectomy from six hours after onset to up to 24 hours after onset
for patients with salvageable brain tissue.

Following the awards ceremony, Dr. Albers will present the results of
the DEFUSE 3 study to members of Congress and discuss the critical role
of federal funding for clinical research.

“My team and I are honored to receive the Distinguished Clinical
Research Achievement Award,” said Dr. Albers. “It is incredibly
gratifying to know that our findings have helped change the landscape
for the diagnosis and treatment of ischemic stroke, leading to more
patients being addressed, reducing disabilities and saving lives.”

About iSchemaView

iSchemaView is the worldwide leader in advanced imaging for stroke.
Installed in over 1,000 stroke centers, iSchemaView’s RAPID (automated
CTP, MRI, CTA and ASPECTS), with enhanced AI framework, is the most
advanced stroke imaging platform. In clinical trials, RAPID has been
shown to aid in the selection of patients in early and late-window
stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and
EXTEND. In addition to achieving the best clinical outcomes
and largest treatment effects ever obtained, these landmark studies led
to new American Heart Association and American Stroke Association
guidelines and have dramatically altered the management of acute stroke
around the world. For more information, visit www.RAPID.ai

About the Top Ten Clinical Research Achievement Awards

Recognizing the need to celebrate our nation’s clinical research
accomplishments that involve both innovation and impact on human
disease, the Clinical Research Forum conducts an annual competition to
determine the ten outstanding research accomplishments in the United
States. These major research advances represent a portion of the annual
return on the nation’s investment in the health and future welfare of
its citizens.

About the Clinical Research Forum

The mission of the Clinical Research Forum is to provide leadership to
the national and clinical translational research enterprise and promote
understanding and support for clinical research and its impact on health
and healthcare. For more information, visit www.clinicalresearchforum.org.

Contacts

Peter Evers
Natron Communications
(415) 524-8899
[email protected]

error: Content is protected !!